Jump to start of content

ABIM call wait times may be longer than usual Expand/Collapse the ABIM alert.

Due to high volume, ABIM call wait times may be longer than usual. We know how busy you are, so we apologize for any inconvenience this may cause. You can always send us a message at abim.org/contact.

Coronavirus Updates Expand/Collapse the ABIM alert.

At ABIM we are actively monitoring the ongoing spread of coronavirus (COVID-19) and will post regular updates about any changes to scheduled assessments.
Scheduled for an assessment this year? ABIM is working with Pearson VUE to ensure your safety throughout your exam day. Learn more about what to expect at test centers.
Please follow the United States Centers for Disease Control and Prevention (CDC) for the most up-to-date information on the virus.

Breadcrumb trail:

Pulmonary Disease Board Exam Committee

Expand All | Collapse All

Peter H. S. Sporn, MD, Chair

Peter H. S. Sporn, MD, ChairDr. Sporn, a board certified internist, pulmonologist and critical care specialist, is Professor of Medicine and Cell and Molecular Biology at the Feinberg School of Medicine of Northwestern University. He is Program Director of the Northwestern University Pulmonary and Critical Care Fellowship Program, a position he has held since 1996, and since which time he has directed the training of 75 pulmonary and critical fellows.

Since 2010, Dr. Sporn has been a member of the American Board of Internal Medicine Pulmonary Disease Board Exam Committee. His clinical interests include asthma, chronic obstructive pulmonary disease, eosinophilic respiratory diseases, interstitial lung diseases and sarcoidosis. His research interests include the role of eicosanoids in lung inflammation, eosinophil biology, mechanosignaling in lung injury and repair, innate immunity and lung host defense. He has been supported by the National Institutes of Health and the Department of Veterans Affairs throughout his research career.

Dr. Sporn received his undergraduate degree from the University of Chicago and his medical degree from Wayne State University School of Medicine. He trained in internal medicine at Bronx Municipal Hospital Center (now Jacobi Medical Center)/Albert Einstein College of Medicine and in pulmonary and critical medicine at the University of Michigan.

As of July 2019, Dr. Sporn reported the following external relationships:

Funding for clinical trial expenses and staff, paid to Northwestern University, from the following company:

  • aTyr Pharma

Attendance at investigators’ meetings, with compensation for travel expenses from the following company:

  • aTyr Pharma

Dr. Sporn serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Thoracic Society, Scientific Advisory Committee, receiving reimbursement for travel expenses.
  • National Institutes of Health, Grant Reviewer, receiving reimbursement for travel expenses.
  • Veterans Affairs, Grant Reviewer, receiving reimbursement for travel expenses.

Grant funding from not-for-profit healthcare-related organizations for project expenses, paid to Northwestern University, from the following organizations:

  • American Thoracic Society
  • National Institutes of Health
  • Foundation for Sarcoidosis Research

Ellen L. Burnham, MD

Ellen L. Burnham, MDDr. Burnham is an Associate Professor of Medicine in the Division of Pulmonary Sciences and Critical Care Medicine at the University of Colorado. She is board certified in Pulmonary Disease and Critical Care Medicine. Currently, she is Medical Director for the University of Colorado Hospital Medical Intensive Care Unit and Associate Program Director for the Colorado Clinical and Translational Science Institute’s KL2 Program.

Previously, Dr. Burnham conducted National Institute of Health-sponsored research to understand the relationship between alcohol abuse and the development of pulmonary diseases that include pneumonia and the acute respiratory distress syndrome (ARDS). In this capacity, she has been the Principal Investigator for a clinically oriented research resource, known as the Colorado Pulmonary Alcohol Research Collaborative (CoPARC) to support translational research in the field. Additionally, she has served as a co-investigator in multi-center clinical trials testing new therapies for ARDS and sepsis. Dr. Burnham has also been a co-investigator for an NIH-supported mentoring training trial with other Clinical and Translational Science Institutes, and has co-authored a number of papers related to the importance of mentor support for clinical and translational research.

Dr. Burnham is a member of the American Board of Internal Medicine Pulmonary Disease Board Exam Committee. She is also an active member of the American Thoracic Society’s (ATS) Assembly on Critical Care, where she has previously served on the Planning Committee and is currently a member of the Programming Committee. She was Chair of the Women in Critical Care working group whose mission has been to improve women’s representation and diversity in the activities of ATS, and in critical care more generally. She is a member of ATS’s Tobacco Action Committee, where her focus is to address the emerging effects of cannabis use on lung health.

Dr. Burnham received biology and chemistry degrees from Texas Christian University, and her medical degree from the University of Texas-Southwestern Medical School. She completed house staff training at the University of Texas-Southwestern Medical School, and her pulmonary/critical care fellowship training at Emory University.

As of July 2019, Dr. Burnham reported the following external relationship:

Dr. Burnham serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • American Thoracic Society, Chair of Women in Critical Care, Tobacco Action Committee Member, without compensation.

Jacqueline Chang, MD

Dr. Chang is a pulmonary critical care physician in practice at Scripps Clinic in La Jolla, California since 1999. She isboard certified in Internal Medicine, Critical Care, and Pulmonary Medicine, and currently the division head of Pulmonary, Critical Care, and Sleep Medicine at Scripps Clinic, a position she has held since 2006. She has also the Medical Director for all the pulmonary function laboratories at Scripps Clinic and Medical Director of the Thoracic Oncology Service. In addition, she is an affiliate appointment with MD Anderson through the partnership between Scripps and MD Anderson. She has also served important leadership roles in Scripps Clinic Medical Group including the Medical Executive Committee and the leadership selection committees.

Dr. Chang received my undergraduate degree (bachelors of arts and sciences) in biology and economics with honors in both through Stanford University. She received my medical degree and internal medicine residency training through Stanford University. She completed my subspecialty training in pulmonary and critical care medicine at the University of Washington , where she also obtained a masters in epidemiology through their School of Public health.

Her current responsibilities are primarily clinical practice with a particular emphasis on fibrosing parenchymal lung disease, along with commitment to my administrative duties, including teaching of internal medicine residents, and some clinical research.

Dr. Chang received her undergraduate degree in biology and economics with honors in both through Stanford University. She received her medical degree and internal medicine residency training through Stanford University. She completed her subspecialty training in pulmonary and critical care medicine at the University of Washington, where she also obtained a masters in epidemiology through their School of Public health.

As of August 2019, Dr. Chang reported the following external relationship:

Service on a research-related advisory board for the following companies, with honoraria:

  • Genentech

Anne E. Dixon, MA, BM BCh

Dr. Dixon is Director of Pulmonary and Critical Care Medicine at the University of Vermont Larner College of Medicine. She is board certified in Pulmonary Disease and Critical Care Medicine.

Since 2001, Dr. Dixon has been an attending physician in the pulmonary and critical care division at the University of Vermont Medical Center. She has served on numerous committees for this organization, including serving as a member of the Board of Trustees of the University of Vermont Medical Group. In addition, she also leads an active research program in obesity and lung disease at the University of Vermont.

Dr. Dixon is a member of the American Board of Internal Medicine Pulmonary Disease Board Exam Committee. She has served on numerous national committees and review boards for the American Thoracic Society, the American Lung Association-Airways Clinical Research Centers, the National Institutes of Health and the Veteran’s Administration.

She received a degree in natural sciences from the University of Cambridge and her medical degree from Oxford University. Dr. Dixon completed residency training at the Johns Hopkins Hospital and fellowship training at the University of Washington.

As of August 2019, Dr. Dixon reported the following external relationship:

Work as an author or editor for the following company, with compensation as listed

  • Springer, receiving compensation for authorship.

Dr. Dixon serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • American Lung Association, Board Member, without compensation.

Dr. Dixon also reports receiving grant funding from the National Institutes of Health.

Karen A. Fagan, MD

Karen A. Fagan, MDDr. Fagan is Chief, Division of Pulmonary and Critical Care Medicine where she is now a Professor of Medicine and Pharmacology, member of the Center for Lung Biology and Director of the USA Pulmonary Hypertension Center. Prior to this role, Dr. Fagan was a faculty member in the Division of Pulmonary Sciences and Critical Care Medicine at the University of Colorado, eventually rising to Associate Professor. At Colorado, she developed a clinical and scientific interest in pulmonary hypertension and received a NIH K08 award followed by R01s and other extramural and intramural funding. In addition, she has served on numerous committees and leadership positions in the Pulmonary Hypertension Association and the American Thoracic Society.

Dr. Fagan has maintained certification in Internal Medicine, Pulmonary Medicine and Critical Care Medicine continuously since 1995 and strongly supports the mission of the ABIM to improve healthcare by certifying providers with the necessary knowledge to provide excellent care to their patients and the community.

Dr. Fagan graduated with BA and Mdher bachelor’s and medical degrees from the University of California San Diego and completed internship and residency in Internal Medicine at the University of Texas Southwestern Medical School in Dallas, TX. After residency, she completed fellowship training in Pulmonary and Critical Care Medicine at the University of Colorado in Denver, CO

As of August 2019, Dr. Fagan reported the following external relationship:

Funding for clinical trial expenses, paid to the University of South Alabama, from the following company:

  • United Therapeutics, for a trial of inhaled treprostinil in patients with interstitial lung disease and pulmonary arterial hypertension.

Post-marketing clinical research, with funding for expenses provided to the University of South Alabama, from the following company:

  • Actelion, for a registry of patients with pulmonary arterial hypertension treated with selexipag.

Work as an author or editor for following company, with compensation as listed:

  • UpToDate®, receiving annual royalties for online educational resource for lymphocytic interstitial pneumonia.

Dr. Fagan serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Thoracic Society, Member, Board of Directors; Chair, Pulmonary Circulation Assembly, receiving reimbursement for travel expenses.
  • Pulmonary Hypertension Association, Chair, Board of Trustees; Immediate Past-Chair of Scientific Leadership Council, receiving reimbursement for travel expenses.

Dr. Fagan also reported that she receives honoraria for serving on two data and safety monitoring boards for the National Institutes of Health for clinical trials on pulmonary arterial hypertension. She also serves as a grant reviewer for the National Institutes of Health.

Joseph M. Forrester, MD

Joseph M. Forrester, MDDr. Forrester is President of Critical Care and Pulmonary Consultants, P.C. He has held this position, overseeing the pulmonary, critical care and internal medicine hospital care provided at the hospitals serviced by Critical Care and Pulmonary Consultants since 1995. The 85-physician practice provides outpatient and inpatient pulmonary and sleep services, inpatient critical care services, and hospitalist services to five hospitals in the Denver, Colorado metropolitan area. Dr. Forrester is also Director of Hospitalist Services of the Intensive Care Unit at The Medical Center of Aurora.

He served four years as a physician in the United States Navy, with two years at Bethesda Naval Hospital and the Uniformed Services Medical School. In addition, he is a Fellow of the American College of Physicians and the American College of Chest Physicians.

Dr. Forrester is a member of the American Board of Internal Medicine Pulmonary Disease Board Exam Committee. He is board certified in Internal Medicine, Pulmonary Disease, Critical Care Medicine and Sleep Medicine.

He earned a degree in chemistry from Kalamazoo College and a medical degree with high distinction from Wayne State University. Dr. Forrester completed his internal medicine house staff training and chief residency at The University of Michigan Hospitals and his pulmonary and critical care training at the University of Colorado Health Science Center.

As of April 2019, Dr. Forrester reported no external relationships.

Neil S. Freedman, MD

Neil S. Freedman, MDDr. Freedman is the Division Head of Pulmonary, Critical Care, Allergy and Immunology at the Northshore University Health System in Evanston, Illinois. He holds the academic rank of Clinical Associate Professor of Medicine at the University of Chicago Pritzker School of Medicine and he is board certified in Pulmonary Disease, Critical Care Medicine and Sleep Medicine. At Northshore, he spends approximately 80% of his time in direct patient care activities with the remainder of his time dedicated to administrative responsibilities. In addition to his clinical and administrative roles, he serves on the Board of Trustees of The Northshore Medical Group Faculty Practice Associates and is Vice President of the Professional Staff.

Previously, Dr. Freedman was in private practice for 12 years as a partner in Pulmonary Physicians of the Northshore in Bannockburn, Illinois.

Dr. Freedman is a member of the American Board of Internal Medicine Pulmonary Disease Board Exam Committee. He has volunteered for several professional societies in leadership and educational roles. He currently serves as a member of the American College of Chest Physicians (ACCP) Chest Foundation Board of Trustees, has recently chaired the ACCP sleep network and previously served on the ACCP joint finance oversight and education committees. He has been a member of the ACCP and Associated Professional Sleep Societies scientific program committees and was the chair of the scientific program committee for CHEST Annual meeting in 2016.

As an educator and clinician, Dr. Freedman has delivered more than 250 presentations at national and international meetings on the topics of sleep, pulmonary and critical care medicine. He has chaired post-graduate courses and general sessions at national meetings for several professional societies and recently was the chair of the ACCP Sleep Medicine Board Review Course from 2013 to 2016. His educational efforts have been recognized with the Excellence in Education Award from the American Academy of Sleep Medicine in 2016 and the ACCP Distinguished Chest Educator in 2017.

Dr. Freedman received a biology degree from Washington and Jefferson College in Washington, Pennsylvania, and his medical degree at the Mount Sinai School of Medicine in New York. He completed his internship and residency in internal medicine and fellowships in pulmonary, critical care and sleep medicine at the Hospital of the University of Pennsylvania.

As of February 2019, Dr. Freedman reported the following external relationship:

Work as an author or editor for the following company, with compensation as listed:

  • UpToDate®, receiving compensation for authorship.

Dr. Freedman serves in significant roles with the following organization, receiving reimbursement or compensation as listed:

  • American College of Chest Physicians, Member of Board of Trustees and Board of Regents, Faculty receiving reimbursement for travel expenses.

Nishant Gupta, MD, MS

Nishant Gupta MD, MSDr. Gupta completed his medical training at the University of Delhi, India, followed by internal medicine residency at the University of Tennessee and fellowships in pulmonary and critical care medicine at the University of Cincinnati. In addition, he has completed fellowship training in the field of rare lung diseases, as well as a master’s degree in Clinical and Translational Research at the University of Cincinnati. Dr. Gupta is ABIM Board Certified in Internal Medicine, Pulmonary Disease and Critical Care Medicine, and is participating in Maintenance of Certification.

Dr. Gupta completed his medical training at the University of Delhi, India, followed by internal medicine residency at the University of Tennessee and fellowships in pulmonary and critical care medicine at the University of Cincinnati. In addition, he has completed fellowship training in the field of rare lung diseases, as well as a master’s degree in Clinical and Translational Research at the University of Cincinnati.

As of March 2020, Dr. Gupta reported the following external relationships:

Funding for clinical trial expenses, salary support and staff, paid to University of Cincinnati from the following companies:

  • Bellerophon Therapeutics, Site Principal Investigator, receiving funding for salary support and project expenses.
  • Boehringer Ingelheim, Site Principal Investigator, receiving funding for salary support and project expenses.
  • Celgene, Site Principal Investigator, receiving funding for salary support and project expenses.
  • Fibrogen, Site Principal Investigator, receiving funding for salary support and project expenses.
  • Galapagos, Site Principal Investigator, receiving funding for salary support and project expenses.
  • Galecto Biotech, Site Principal Investigator, receiving funding for salary support and project expenses.

Work as an author or editor for the following company, with compensation as listed:

  • UpToDate®, receiving compensation for authorship.

Dr. Gupta serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • The LAM Foundation, Member, Scientific Advisory Board, without compensation.
  • Tuberous Sclerosis Alliance, Tuberous Sclerosis Complex Bio-Sample Repository and Natural History Database Project, Steering Committee Member, without compensation.

Dr. Gupta also reported receiving funding for clinical trial salary support from the National Institutes of Health, paid to the University of Cincinnati, for the following trials:

  • Principal Investigator for R34HL138235 (RESULT).
  • Co-Principal Investigator for U01HL131755-01 (MILED.
  • Co-Principal Investigator for R01 LM012230 (ICU EHR).
  • Co-Principal Investigator for R01HL143011-01A1 (IPF MRI).
  • Co-Principal Investigator for R21AI137309 (IL-31 in IPF.
  • Co-Principal Investigator for U01HL1285954 (CleanUP IPF).

Nadia N. Hansel, MD

Nadia N. Hansel, MDDr. Nadia Hansel is a Professor of Medicine and Interim Director of the Division of Pulmonary and Critical Care Medicine at Johns Hopkins with joint appointments in the Division of Allergy and Clinical Immunology at the Johns Hopkins School of Medicine and the Department of Environmental Health Sciences at the Johns Hopkins Bloomberg School of Public Health. She assumed the position of the Associate Dean of Research for the Bayview Campus, Johns Hopkins University School of Medicine in July 2014.

Dr. Hansel's research is focused on environmental determinants of obstructive lung diseases. She is widely recognized as an international expert in defining the indoor air quality on asthma and chronic obstructive pulmonary disease (COPD) health.

Her work is funded by the National Institutes of Health, Housing of Urban Development and the Environmental Protection Agency. Dr. Hansel is the Director of the Johns Hopkins Center for the Study of the Childhood Asthma in the Urban Environment (CCAUE) and the Director of the Johns Hopkins Center of Excellence on Environmental Health Disparities Research. In addition, Dr. Hansel serves on numerous editorial boards and professional organizations, is frequently an invited speaker nationally and internationally to present her research and has published over 150 peer reviewed publications. She received the David M. Levine Excellence in Mentoring Award in recognition of her dedication to training future physician scientists. Dr. Hansel serves on the American Board of Internal Medicine Pulmonary Disease Exam Board.

She received her undergraduate degree magna cum laude in biology from Harvard College and her medical degree from Harvard Medical School. Her internal medicine residency was completed at the University of Pennsylvania and she came to Johns Hopkins University to complete her Pulmonary and Critical Care fellowship. She subsequently completed her Master of Public Health degree from the Johns Hopkins Bloomberg School of Public Health.

As of May 2020, Dr. Hansel reported the following external relationship:

Service on a research-related advisory board for the following companies, with honoraria:

  • AstraZeneca

Funding for clinical research staff and expenses, paid to Johns Hopkins University, from the following non-profit healthcare-related organizations:

  • Chronic Obstructive Pulmonary Disease Foundation
  • National Institutes of Health, receiving funding for studies relating to chronic obstructive pulmonary disease, asthma, and indoor air pollution.

M. Patricia Rivera, MD

Dr. Rivera is a Professor of Medicine in the Division of Pulmonary Diseases and Critical Care Medicine at the University of North Carolina at Chapel Hill. I am Board certified in Internal Medicine and Pulmonary Diseases. She specializes in lung cancer screening, diagnosis, staging, and management of treatment complications and currently serves as co-Director of the Multidisciplinary Thoracic Oncology Program and Director of the Lung Cancer Screening (LCS) Program at UNC.

She is the currently Chair of the Thoracic Oncology Network of the ACCP and immediate past Chair of the Thoracic Oncology Assembly of the ATS. She has led ATS research workshops on the impact of co-morbidities on LCS, disparities in LCS, and immunotherapy induced lung disease. She serves as Vice Chair of the Lung Cancer in Women Task Force and of the Biomarker Task Force of the National Lung Cancer Round Table (NLCRT), charged to promote awareness of lung cancer as a women's health imperative and barriers to biomarker testing.

Her research interests include lung cancer in women and lung cancer screening. Dr. Rivera is an active participant in the ACCP Lung Cancer Guidelines Initiative and have had an integral part in the guideline's development. She is currently an investigator in NIH funded grants to examine the delivery, quality and outcomes of lung cancer screening in North Carolina, and co-PI of a study to explore rural/urban disparities associated with biomarker testing. Throughout her career, she has worked effectively in multidisciplinary clinical and research settings, using my expertise in lung cancer to promote evidence-based screening, diagnosis, staging and treatment.

As of August 2019, Dr. Rivera reported the following external relationships:

Service on a research-related advisory board for the following companies, with compensation for travel expenses and honoraria:

  • Biodesix Technologies, member of the medical and scientific advisory panel to design a multi-institutional trial to evaluate a serum biomarker in incidentally-detected nodules.
  • BioAffinity Technologies, chair of medical and scientific advisory panel.

Dr. Rivera serves in significant roles with the following organizations, receiving reimbursement or compensation as listed:

  • American Thoracic Society, Chair, Thoracic Oncology Assembly and Board Member, without compensation.
  • American College of Chest Physicians, Chair, Thoracic Oncology Network, without compensation.
  • American Cancer Society, National Lung Cancer Round Table Member, Vice-Chair, Lung Cancer in Women Task Force, Member of Triage for Appropriate Treatment Task Force, without compensation.

Grant funding for salary support, paid to the University of North Carolina-Chapel Hill, from nonprofit healthcare-related organization:

  • National Cancer Institute, for an R01 Grant.